Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

BMC Infectious Diseases

Table 5 Genotype and allele frequency distributions among patients with or without neuropsychiatric disorders during efavirenz based HAART

Genotype		Neuropsychiatric disorders				p value
			No		Yes
		n	%	n	%
CYP2B6*6	1/1	21	42	61	44.5	0.16
	1/6	28	56	63	46
	6/6	1	2	13	9.5
CYP2B6*11	1/1	41	82	111	78.2	0.17
	1/11	8	16	31	21.8
	11/11	1	2	0	0
CYP2A6*9	1/1	39	84.8	98	79.7	0.51
	1/9	7	15.2	22	17.9
	9/9	0	0	3	2.4
CYP2A6*17	1/1	38	90.5	104	83.9	0.3
	1/17	3	7.1	19	15.3
	17/17	1	2.4	1	0.8
No. of CYP3A5*1 alleles^a	zero	15	30	31	21.8	0.48
	One	24	48	79	55.6
	Two	11	22	32	22.5
ABCB1 (rs3842	0/0	29	63	87	65.4	0.95
	0/1	16	34.8	43	32.3
	1/1	1	2.2	3	2.3
ABCB1 c.3435C/T	CC	37	74	109	77.9	0.68
	CT	13	26	30	21.4
	TT	0	0	1	0.7
NR1I3 rs3003569CT	TT	10	21.7	29	23	0.06
	TC	16	34.8	65	51.6
	CC	20	43.5	32	25.4
Alleles		Frequency (%)		Frequency (%)
CYP2B6*6		30		32.5		0.21
CYP2B6*11		10		10.9		0.78
CYP2A6*9		7.61		11.38		0.31
CYP2A6*17		5.95		8.46		0.55
No. of CYP3A5*1 allele		46		50.4		0.56
ABCB1 rs3842		19.6		18.4		0.80
ABCB1 c.3435T		13		11.4		0.67
NR1I3 rs3003569 T		39.1		48.8		0.11

P value from binary logistic regression is presented.
^a Haplotype analyses indicate no linkage between CYP3A5 SNPs thus subjects were grouped based on number of functional CYP3A5 allele (CYP3A5*1) for statistical analysis.